Please try another search
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Issac Kim | - | - | Member of Clinical Advisory Board |
Young-Jung Kwon | - | - | Director |
John Letterio | - | - | Member of Clinical Advisory Board |
Young- Sik Kim | - | - | Director |
Youn- Sik Song | - | - | Director |
Gregory Licholai | - | - | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review